Preventable fractions of cervical cancer via effective screening in six Baltic, central, and eastern European countries 2017–40: a population-based study

The Lancet Oncology

Volumn 17, Issue 10, 2016, Pages 1445-1452

  Vaccarella, Salvatore ^a   Franceschi, Silvia ^a   Zaridze, David ^b   Poljak, Mario ^c   Veerus, Piret ^d   Plummer, Martyn ^a   Bray, Freddie ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

^d National Institute for Health Development   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BELARUS; BULGARIA; CANCER GROWTH; CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; COHORT ANALYSIS; CONTROLLED STUDY; ESTONIA; FEMALE; HUMAN; LATVIA; LITHUANIA; PAPILLOMAVIRUS INFECTION; POPULATION RESEARCH; PRIORITY JOURNAL; RUSSIAN FEDERATION; TREND STUDY; UTERINE CERVIX CANCER; EARLY CANCER DIAGNOSIS; EASTERN EUROPE; IMMUNOLOGY; MIDDLE AGED; UTERINE CERVICAL NEOPLASMS; VACCINATION;

WART VIRUS VACCINE;

ADULT; AGED; EARLY DETECTION OF CANCER; EUROPE, EASTERN; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84992336054     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30275-3     Document Type: Article

References (44)

1. 1 Ferlay, J, Soerjomataram, I, Dikshit, R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
2. 2 Arbyn, M, Antoine, J, Magi, M, et al. Trends in cervical cancer incidence and mortality in the Baltic countries, Bulgaria and Romania. Int J Cancer 128 (2011), 1899–1907.
3. 3 Vaccarella, S, Lortet-Tieulent, J, Plummer, M, Franceschi, S, Bray, F, Worldwide trends in cervical cancer incidence: Impact of screening against changes in disease risk factors. Eur J Cancer 49 (2013), 3262–3273.
4. 4 Bray, F, Lortet-Tieulent, J, Znaor, A, Brotons, M, Poljak, M, Arbyn, M, Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia. Vaccine 31:suppl 7 (2013), H32–H45.
5. 5 Poljak, M, Seme, K, Maver, PJ, et al. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe. Vaccine 31:suppl 7 (2013), H59–H70.
6. 6 Van de Velde, N, Boily, MC, Drolet, M, et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst 104 (2012), 1712–1723.
7. 7 Vaccarella, S, Franceschi, S, Engholm, G, Lonnberg, S, Khan, S, Bray, F, 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer 111 (2014), 965–969.
8. 8 Foley, G, Alston, R, Geraci, M, Brabin, L, Kitchener, H, Birch, J, Increasing rates of cervical cancer in young women in England: an analysis of national data 1982–2006. Br J Cancer 105 (2011), 177–184.
9. 9 Peto, J, Gilham, C, Fletcher, O, Matthews, FE, The cervical cancer epidemic that screening has prevented in the UK. Lancet 364 (2004), 249–256.
10. 10 Simms, I, Fairley, CK, Epidemiology of genital warts in England and Wales: 1971 to 1994. Genitourin Med 73 (1997), 365–367.
11. 11 Laukkanen, P, Koskela, P, Pukkala, E, et al. Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol 84 (2003), 2105–2109.
12. 12 Uuskula, A, Puur, A, Toompere, K, DeHovitz, J, Trends in the epidemiology of bacterial sexually transmitted infections in eastern Europe, 1995–2005. Sex Transm Infect 86 (2010), 6–14.
13. 13 Tichonova, L, Borisenko, K, Ward, H, Meheus, A, Gromyko, A, Renton, A, Epidemics of syphilis in the Russian Federation: trends, origins, and priorities for control. Lancet 350 (1997), 210–213.
14. 14 Laara, E, Day, NE, Hakama, M, Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1 (1987), 1247–1249.
15. 15 IARC. IARC Handbooks of Cancer Prevention Volume 10: Cervix Cancer Screening, 2005, IARC Press, Lyon http://www.iarc.fr/en/publications/pdfs-online/prev/handbook10/HANDBOOK10.pdf (accessed June 21, 2016).
16. 16 United Nations Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2012 revision, highlights and advance tables. Working paper no. ESA/P/WP.228. https://esa.un.org/unpd/wpp/publications/Files/WPP2012_HIGHLIGHTS.pdf (accessed June 21, 2016).
17. 17 Doll, R, Payne, P, Waterhouse, J, Cancer Incidence in Five Continents, vol. 1, 1966, Union Internationale Contre le Cancer, Geneva.
18. 18 Clayton, D, Schifflers, E, Models for temporal variation in cancer rates. I: age-period and age-cohort models. Stat Med 6 (1987), 449–467.
19. 19 Plummer, M, Peto, J, Franceschi, S, Time since first sexual intercourse and the risk of cervical cancer. Int J Cancer 130 (2012), 2638–2644.
20. 20 Bray, F, Loos, AH, McCarron, P, et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 14 (2005), 677–686.
21. 21 Moller, B, Fekjaer, H, Hakulinen, T, et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. Stat Med 22 (2003), 2751–2766.
22. 22 Vaccarella, S, Franceschi, S, Bray, F, The incremental benefits of implementing effective cervical cancer screening. Int J Cancer 138 (2015), 254–255.
23. 23 Rogovskaya, SI, Shabalova, IP, Mikheeva, IV, et al. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia. Vaccine 31:suppl 7 (2013), H46–H58.
24. 24 Campos, NG, Castle, PE, Wright, TC Jr, Kim, JJ, Cervical cancer screening in low-resource settings: a cost-effectiveness framework for valuing tradeoffs between test performance and program coverage. Int J Cancer 137 (2015), 2208–2219.
25. 25 Maver, PJ, Seme, K, Korac, T, et al. Cervical cancer screening practices in central and eastern Europe in 2012. Acta Dermatovenerol Alp Pannonica Adriat 22 (2013), 7–19.
26. 26 Altobelli, E, Lattanzi, A, Cervical carcinoma in the European Union: an update on disease burden, screening program state of activation, and coverage as of March 2014. Int J Gynecol Cancer 25 (2015), 474–483.
27. 27 Arbyn, M, Anttila, A, Jordan, J, et al. (eds.) European guidelines for quality assurance in cervical cancer screening, Second edn., 2008, Office for Official Publications of the European Communities, Luxembourg, 291 http://bookshop.europa.eu/en/european-guidelines-for-quality-assurance-in-cervical-cancer-screening-pbND7007117/ (accessed June 21, 2016).
28. 28 Elfstrom, KM, Arnheim-Dahlstrom, L, von, KL, Dillner, J, Cervical cancer screening in Europe: Quality assurance and organisation of programmes. Eur J Cancer 51 (2015), 950–968.
29. 29 Viberga, I, Poljak, M, Cervical cancer screening in Latvia: a brief history and recent improvements (2009–2011). Acta Dermatovenerol Alp Pannonica Adriat 22 (2013), 27–30.
30. 30 Poljak, M, Rogovskaya, SI, Kesic, V, et al. Recommendations for cervical cancer prevention in Central and Eastern Europe and Central Asia. Vaccine 31:suppl 7 (2013), H80–H82.
31. 31 Bosch, FX, Robles, C, Diaz, M, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol 13 (2015), 119–132.
32. 32 WHO. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention, 2013, World Health Organization, Geneva http://apps.who.int/iris/bitstream/10665/94830/1/9789241548694_eng.pdf (accessed June 21, 2016).
33. 33 Carstensen, B, Age-period-cohort models for the Lexis diagram. Stat Med 26 (2007), 3018–3045.
34. 34 Holford, TR, Understanding the effects of age, period, and cohort on incidence and mortality rates. Annu Rev Public Health 12 (1991), 425–457.
35. 35 Dimitrov, BD, Cyclic patterns of cancer incidence in males by body site: data from the USA for the period 1973–1989. J BUON 5 (2000), 81–84.
36. 36 Xu, M, Powers, DA, Bayesian ridge estimation of age-period-cohort models. Schoen, R, (eds.) Dynamic Demographic Analysis, 2016, Springer International Publishing, Switzerland, 337–359.
37. 37 Mistry, M, Parkin, DM, Ahmad, AS, Sasieni, P, Cancer incidence in the United Kingdom: projections to the year 2030. Br J Cancer 105 (2011), 1795–1803.
38. 38 Moller, H, Fairley, L, Coupland, V, et al. The future burden of cancer in England: incidence and numbers of new patients in 2020. Br J Cancer 96 (2007), 1484–1488.
39. 39 Sasieni, P, Adams, J, Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 357 (2001), 1490–1493.
40. 40 Bray, F, Moller, B, Predicting the future burden of cancer. Nat Rev Cancer 6 (2006), 63–74.
41. 41 Moller, B, Weedon-Fekjaer, H, Haldorsen, T, Empirical evaluation of prediction intervals for cancer incidence. BMC Med Res Methodol, 5, 2005, 21.
42. 42 Rutherford, MJ, Thompson, JR, Lambert, PC, Projecting cancer incidence using age-period-cohort models incorporating restricted cubic splines. Int J Biostat, 8, 2012, 33.
43. 43 Parkin, DM, Bray, F, Ferlay, J, Jemal, A, Cancer in Africa 2012. Cancer Epidemiol Biomarkers Prev 23 (2014), 953–966.
44. 44 Engholm, G, Ferlay, J, Christensen, N, et al. NORDCAN—a Nordic tool for cancer information, planning, quality control and research. Acta Oncol 49 (2010), 725–736.